Company profile: Purespring Therapeutics
1.1 - Company Overview
Company description
- Provider of AAV gene therapy programs for kidney diseases, targeting podocytes to address monogenic and more common forms, and the FunSel in‑vivo AAV-based screening platform that utilizes libraries of biological factors to identify new kidney gene therapy candidates.
Products and services
- Gene Therapy for Kidney Diseases: Purespring architects AAV-based therapies targeting podocytes to treat monogenic and more common kidney diseases, focusing on specialized kidney cell delivery and renal condition specificity
- FunSel Screening Platform: This in-vivo platform assesses a library of biological factors encoded in AAV vectors to identify new kidney disease gene therapy candidates within relevant tissue environments
- AAV Vector Library: An AAV-encoded collection of biological factors used to identify kidney gene therapy candidates in vivo.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Purespring Therapeutics
Talphera
HQ: United States
Website
- Description: Provider of therapies for the treatment of pain and other conditions, focusing on development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Talphera company profile →
A1M Pharma
HQ: Sweden
Website
- Description: Provider of alpha 1 microglobulin, a body protein that is of major importance for the body's defense against oxidative stress.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full A1M Pharma company profile →
Outset Medical
HQ: United States
Website
- Description: Provider of dialysis technology, including the Tablo Hemodialysis System for treating acute and chronic renal failure in hospitals and at home, featuring integrated water purification, touchscreen interface, and multiple dialysis modalities; TabloHub for two-way data transmission and remote patient monitoring; EMR Connect for EMR integration and automated documentation; and TabloCart for device transportation within clinical settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Outset Medical company profile →
Guard Therapeutics
HQ: Sweden
Website
- Description: Provider of drug candidates for oxidative stress and kidney disease, including RMC-035, a biological therapy mimicking human A1M to prevent acute kidney injury during open-heart surgery, kidney transplantation or sepsis, and GTX-peptider, preclinical A1M fragment–mimicking peptides intended for chronic treatment of kidney diseases and self-administration via subcutaneous injection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Guard Therapeutics company profile →
Angion Biomedica
HQ: United States
Website
- Description: Provider of clinical-stage organ restoration biopharmaceuticals focused on renal disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Angion Biomedica company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Purespring Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Purespring Therapeutics
2.2 - Growth funds investing in similar companies to Purespring Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Purespring Therapeutics
4.2 - Public trading comparable groups for Purespring Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →